841 related articles for article (PubMed ID: 24636821)
1. From bench to bedside: An overview of rotigotine for the treatment of restless legs syndrome.
Bogan RK
Clin Ther; 2014 Mar; 36(3):436-55. PubMed ID: 24636821
[TBL] [Abstract][Full Text] [Related]
2. Long-term safety and efficacy of rotigotine transdermal patch for moderate-to-severe idiopathic restless legs syndrome: a 5-year open-label extension study.
Oertel W; Trenkwalder C; Beneš H; Ferini-Strambi L; Högl B; Poewe W; Stiasny-Kolster K; Fichtner A; Schollmayer E; Kohnen R; García-Borreguero D;
Lancet Neurol; 2011 Aug; 10(8):710-20. PubMed ID: 21705273
[TBL] [Abstract][Full Text] [Related]
3. Rotigotine transdermal delivery for the treatment of restless legs syndrome.
Sixel-Döring F; Trenkwalder C
Expert Opin Pharmacother; 2010 Mar; 11(4):649-56. PubMed ID: 20163275
[TBL] [Abstract][Full Text] [Related]
4. One year open-label safety and efficacy trial with rotigotine transdermal patch in moderate to severe idiopathic restless legs syndrome.
Oertel WH; Benes H; Garcia-Borreguero D; Geisler P; Högl B; Trenkwalder C; Tacken I; Schollmayer E; Kohnen R; Stiasny-Kolster K;
Sleep Med; 2008 Dec; 9(8):865-73. PubMed ID: 18753003
[TBL] [Abstract][Full Text] [Related]
5. Rotigotine Transdermal Patch: A Review in Restless Legs Syndrome.
Garnock-Jones KP
Drugs; 2016 Jul; 76(10):1031-40. PubMed ID: 27324269
[TBL] [Abstract][Full Text] [Related]
6. Clinical pharmacology and efficacy of rotigotine (Neupro® patch) in the treatment of restless leg syndrome.
Ferini-Strambi L; Marelli S; Galbiati A
Expert Opin Drug Metab Toxicol; 2016 Aug; 12(8):967-75. PubMed ID: 27224246
[TBL] [Abstract][Full Text] [Related]
7. An update on pharmacological, pharmacokinetic properties and drug-drug interactions of rotigotine transdermal system in Parkinson's disease and restless legs syndrome.
Elshoff JP; Cawello W; Andreas JO; Mathy FX; Braun M
Drugs; 2015 Apr; 75(5):487-501. PubMed ID: 25795100
[TBL] [Abstract][Full Text] [Related]
8. Treatment of moderate to severe restless legs syndrome: 2-year safety and efficacy of rotigotine transdermal patch.
Högl B; Oertel WH; Stiasny-Kolster K; Geisler P; Beneš H; García-Borreguero D; Trenkwalder C; Poewe W; Schollmayer E; Kohnen R
BMC Neurol; 2010 Sep; 10():86. PubMed ID: 20920156
[TBL] [Abstract][Full Text] [Related]
9. Rotigotine transdermal patch: in restless legs syndrome.
Baldwin CM; Keating GM
CNS Drugs; 2008; 22(10):797-806. PubMed ID: 18788832
[TBL] [Abstract][Full Text] [Related]
10. A method to switch from oral dopamine agonists to rotigotine in patients with restless legs syndrome and mild augmentation.
Winkelman JW; Mackie SE; Mei LA; Platt S; Schoerning L
Sleep Med; 2016 Aug; 24():18-23. PubMed ID: 27810181
[TBL] [Abstract][Full Text] [Related]
11. Rotigotine: transdermal dopamine agonist treatment of Parkinson's disease and restless legs syndrome.
Splinter MY
Ann Pharmacother; 2007 Feb; 41(2):285-95. PubMed ID: 17213296
[TBL] [Abstract][Full Text] [Related]
12. Rotigotine transdermal patch for the treatment of Parkinson's disease and restless legs syndrome.
Boroojerdi B; Wolff HM; Braun M; Scheller DK
Drugs Today (Barc); 2010 Jul; 46(7):483-505. PubMed ID: 20683503
[TBL] [Abstract][Full Text] [Related]
13. Management of augmentation of restless legs syndrome with rotigotine: a 1-year observational study.
Trenkwalder C; Canelo M; Lang M; Schroeder H; Kelling D; Berkels R; Schollmayer E; Heidbrede T; Benes H
Sleep Med; 2017 Feb; 30():257-265. PubMed ID: 26896370
[TBL] [Abstract][Full Text] [Related]
14. Effects of rotigotine on daytime symptoms in patients with primary restless legs syndrome: a randomized, placebo-controlled study.
Garcia-Borreguero D; Allen R; Hudson J; Dohin E; Grieger F; Moran K; Schollmayer E; Smit R; Winkelman J
Curr Med Res Opin; 2016; 32(1):77-85. PubMed ID: 26569149
[TBL] [Abstract][Full Text] [Related]
15. Patch application of the dopamine agonist rotigotine to patients with moderate to advanced stages of restless legs syndrome: a double-blind, placebo-controlled pilot study.
Stiasny-Kolster K; Kohnen R; Schollmayer E; Möller JC; Oertel WH;
Mov Disord; 2004 Dec; 19(12):1432-8. PubMed ID: 15390055
[TBL] [Abstract][Full Text] [Related]
16. Rotigotine transdermal patch in moderate to severe idiopathic restless legs syndrome: a randomized, placebo-controlled polysomnographic study.
Oertel WH; Benes H; Garcia-Borreguero D; Högl B; Poewe W; Montagna P; Ferini-Strambi L; Sixel-Döring F; Trenkwalder C; Partinen M; Saletu B; Polo O; Fichtner A; Schollmayer E; Kohnen R; Cassel W; Penzel T; Stiasny-Kolster K
Sleep Med; 2010 Oct; 11(9):848-56. PubMed ID: 20813583
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of rotigotine for treatment of moderate-to-severe restless legs syndrome: a randomised, double-blind, placebo-controlled trial.
Trenkwalder C; Benes H; Poewe W; Oertel WH; Garcia-Borreguero D; de Weerd AW; Ferini-Strambi L; Montagna P; Odin P; Stiasny-Kolster K; Högl B; Chaudhuri KR; Partinen M; Schollmayer E; Kohnen R;
Lancet Neurol; 2008 Jul; 7(7):595-604. PubMed ID: 18515185
[TBL] [Abstract][Full Text] [Related]
18. Safety and efficacy of rotigotine transdermal patch in patients with restless legs syndrome: a post-hoc analysis of patients taking 1 - 3 mg/24 h for up to 5 years.
Dohin E; Högl B; Ferini-Strambi L; Schollmayer E; Fichtner A; Bauer L; García-Borreguero D
Expert Opin Pharmacother; 2013 Jan; 14(1):15-25. PubMed ID: 23256574
[TBL] [Abstract][Full Text] [Related]
19. Rotigotine transdermal system: developing continuous dopaminergic delivery to treat Parkinson's disease and restless legs syndrome.
Benitez A; Edens H; Fishman J; Moran K; Asgharnejad M
Ann N Y Acad Sci; 2014 Nov; 1329():45-66. PubMed ID: 25145951
[TBL] [Abstract][Full Text] [Related]
20. Augmentation in the treatment of restless legs syndrome with transdermal rotigotine.
Beneš H; García-Borreguero D; Ferini-Strambi L; Schollmayer E; Fichtner A; Kohnen R
Sleep Med; 2012 Jun; 13(6):589-97. PubMed ID: 22503658
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
